Mouse Oral Squamous Cell Carcinoma (OSCC) Cell Lines

Transplantable mouse OSCC cell lines derived from independent carcinogen-induced tumors.

Highlights

  • MOC1 and MOC22: Indolent growth phenotypes
  • MOC2: Aggressive growth phenotype - ability to form tumors with injection of as few as 10,000 cells

Oral cavity squamous cell carcinoma (OSCC) is a prominent subset of head and neck cancers, which are the 6th most common cancer worldwide. The major risk factor for developing OSCC is carcinogen exposure, which distinguishes this subset of head and neck cancers from those induced by human papillomavirus. Despite advances in detection, surgery, chemotherapy, and radiation, the prognosis for OSCC has remained stable for decades. Furthermore, at the time of diagnosis, approximately two-thirds of OSCC patients have locoregionally advanced disease resulting in increased morbidity and mortality.

From the laboratory of Ravindra Uppaluri, MD, PhD, Washington University in Saint Louis.

Catalog Number Product Size AVAILABILITY Price Qty
EWL001-FP
Mouse OSCC Cell Line (MOC1), 1 vial
1 vial In stock
Price: $599.00
EWL002-FP
Mouse OSCC Cell Line (MOC2), 1 vial
1 vial In stock
Price: $599.00
EWL003-FP
Mouse OSCC Cell Line (MOC22), 1 vial
1 vial In stock
Price: $599.00

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications
Product Type: Cell Line
Cell Type: Mouse oral cancer
Organism: MOC1 and MOC22 were derived from primary tumors in C57BL/6 WT mice. MOC2 was derived from a chemokine receptor CXCR3 deficient mouse on a pure C57BL/6 background (of note, no major differences in the incidence of tumor formation were noted between the different genotypes).
Source: Oral cavity
Biosafety Level: 2
Growth Conditions: PDF Suggested Protocol
Cryopreservation: 10% DMSO
Storage: Ln2
Shipped: Dry Ice
Documentation
Provider
From the laboratory of Ravindra Uppaluri, MD, PhD, Washington University in Saint Louis.
References
  1. Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, Piccirillo JF, Lewis JS Jr, Mardis ER, Uppaluri R. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014 Jun 1;20(11):2873-84. doi: 10.1158/1078-0432.CCR-14-0205. Epub 2014 Mar 25. PubMed PMID: 24668645; PubMed Central PMCID: PMC4096804.
  2. Judd NP, Allen CT, Winkler AE, Uppaluri R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol Head Neck Surg. 2012 Sep;147(3):493-500. doi: 10.1177/0194599812442037. Epub 2012 Mar 19. PubMed PMID: 22434099; PubMed Central PMCID: PMC6346425.
  3. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012 Jan 1;72(1):365-74. doi: 10.1158/0008-5472.CAN-11-1831. Epub 2011 Nov 15. PubMed PMID: 22086849; PubMed Central PMCID: PMC3286642.

If you publish research with this product, please let us know so we can cite your paper.

 
Loading...
Loading...